Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of Doxorubicin /Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D (AC-D) as Front-line Chemotherapy for Metastatic Breast Cancer: Japan Clinical Oncology Group Trial (JCOG9802)

NCT00190489 is registered in ClinicalTrials.gov with Japan Clinical Oncology Group as lead sponsor.

NCT NCT00190489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00190489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of Doxorubicin /Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D (AC-D) as Front-line Chemotherapy for Metastatic Breast Cancer: Japan Clinical Oncology Group Trial (JCOG9802)
Lead sponsor
Japan Clinical Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
January 31, 1999
Completion date
May 31, 2006
Enrollment
450
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, neoplasm metastasis